AGE Reader
Non-invasive cardiovascular risk assessment
Patient friendly diagnosis, Personalized care & Preventing disease
Wish to receive a quotation on product purchasing or leasing?
Quotation request
Key publications
The AGE Reader has been validated in over 200 peer-reviewed publications. Please find below a selection of key publications in several clinical areas:
CV Risk in the general population:
- Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. van Waateringe R et al. Diabetologia. 2019 Feb;62(2):269-280 Epub
CV Risk in Diabetes patients:
- Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Lutgers H. et al, Diabetologia, 2009; 52(5): 789-797
- Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study. Noordzij M.J. et al. Diabet Med. 2012 Dec;29(12):1556-61.
- Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease. Gerrits E. et al. Diabetes Care. 2008; 31: 517-521
- Skin Autofluorescence – A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes. A. Stirban & L. Heinemann European Endocrinology, 2014;10(2):106–10. Full text available.
CV Risk in Atherosclerosis patients:
- Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease. de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.
CV Risk in Kidney disease patients:
- Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Sep 1. Epub
- Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients. Hartog J. et al. Transplantation, Volume 87, Number 7, April 15, 2009.
Technical validation:
- Simple non-invasive assessment of advanced glycation endproducts accumulation. Meerwaldt R et al, Diabetologia, 2004; 47:1324-1330
Interested in receiving a white paper and product brochure? Please leave your name and email here.
More Information
Request information
Would you like to learn more about our products? Request any information you wish to receive here.
The AGE Reader App!
The new AGE Reader App allows you to generate a comprehensive Cardiovascular Risk Report based on the AGE Reader measurement. For each patient all visits can be documented and consulted in the easy to use App.
Read more »
Read more »
About the company
More information about Diagnoptics.
Information for patients
Information on Diagnoptics' products and Advanced Glycation Endproducts.
Information for professionals
Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.